Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Kyowa Kirin Co., Ltd. is currently managing 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 6 distinct examiners and 5 distinct art units. This distribution indicates a diverse portfolio with multiple technical focuses within the biotech sector. The fact that there are 6 distinct examiners for 6 pending office actions shows that no two actions are currently being reviewed by the same person. This variety of reviewers may lead to different prosecution timelines or requirements across the 6 pending office actions.
HUI, SAN MING R is the busiest examiner, though they only have 1 busiest examiner pending action. This 1 busiest examiner pending action reflects the broad distribution of the company's workload, as each of the 6 pending office actions is handled by a different individual. With 5 distinct art units involved, the company is engaging with a wide range of administrative groups at the USPTO. Practitioners should be prepared for a variety of examiner styles and art unit standards. The presence of 5 distinct art units suggests that the company's research and development efforts are technically multifaceted.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §103 only | 2 (29%) |
| Double-patenting only | 1 (14%) |
| Double-patenting + other | 2 (29%) |
| Multi-statute (no §101) | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUI, SAN MING R | 1 | 59.5% | +20.1% |
| CALDERON, DAVID ANDREW | 1 | 100.0% | +0.0% |
| POHNERT, STEVEN C | 1 | 12.4% | +18.5% |
| STEPHENS, AMELIA CAROLE | 1 | 85.7% | +33.3% |
| SIMMONS, CHRIS E | 1 | 34.1% | +19.4% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
| DEBERRY, REGINA M | 1 | 50.1% | +30.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18248238 | METHOD FOR TREATING OX40 RELATED DISEASE | STEPHENS, AMELIA CAROLE | 49d overdue |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18534162 | SYNTHETIC ADSORBENT, ANTIBODY PURIFICATION METHOD, AND ANTIBODY PRODUCTION METHOD | CALDERON, DAVID ANDREW | — |
| 18300892 | METHOD FOR SELECTING CELL | POHNERT, STEVEN C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17916275 | ANTIBODY COMPOSITION | BRISTOL, LYNN ANNE | 59d overdue |
| 18248238 | METHOD FOR TREATING OX40 RELATED DISEASE | STEPHENS, AMELIA CAROLE | 49d overdue |
| 18598208 | PHARMACEUTICAL COMPOSITION | HUI, SAN MING R | — |
| 18300892 | METHOD FOR SELECTING CELL | POHNERT, STEVEN C | — |
| 18118898 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | SIMMONS, CHRIS E | — |
| 17288057 | PHARMACEUTICAL COMPOSITION FOR TREATING APLASTIC ANEMIA | DEBERRY, REGINA M | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1683 | 1 |
| 1645 | 1 |
| 1622 | 1 |
| 1643 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18598208 | PHARMACEUTICAL COMPOSITION | HUI, SAN MING R | 1627 | DP | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18534162 | SYNTHETIC ADSORBENT, ANTIBODY PURIFICATION METHOD, AND ANTIBODY PRODUCTION METHOD | CALDERON, DAVID ANDREW | — | §102§112 | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18300892 | METHOD FOR SELECTING CELL | POHNERT, STEVEN C | 1683 | §101§103§112 | Non-Final OA | — | Pending | Apr 14, 2023 |
| 18248238 | METHOD FOR TREATING OX40 RELATED DISEASE | STEPHENS, AMELIA CAROLE | 1645 | §103 | Non-Final OA | 49d overdue | Pending | Apr 06, 2023 |
| 18118898 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | SIMMONS, CHRIS E | 1622 | §112DP | Non-Final OA | — | Pending | Mar 08, 2023 |
| 17916275 | ANTIBODY COMPOSITION | BRISTOL, LYNN ANNE | 1643 | §103DP | Final Rejection | 59d overdue | Pending | Sep 30, 2022 |
| 17288057 | PHARMACEUTICAL COMPOSITION FOR TREATING APLASTIC ANEMIA | DEBERRY, REGINA M | 1647 | §103 | Non-Final OA | — | Pending | Apr 23, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial